ALAMEDA, Calif., April 25, 2023 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the following investor conferences on the dates and times listed below:
Event: | Bank of America Securities 2023 Health Care Conference |
Date: | Tuesday, May 9, 2023 |
Time: | 1:40pm ET / 10:40am PT |
Event: | 2023 RBC Capital Markets Global Healthcare Conference |
Date: | Tuesday, May 16, 2023 |
Time: | 11:30am ET / 8:30am PT |
Webcasts of the presentations will be available by visiting the investors' section of the company's website at www.penumbrainc.com. The webcasts will be available on the company's website for at least two weeks following the event.
About Penumbra
Penumbra, Inc., headquartered in Alameda, California, is a global healthcare company focused on innovative therapies. Penumbra designs, develops, manufactures and markets novel products and has a broad portfolio that addresses challenging medical conditions in markets with significant unmet need. Penumbra supports healthcare providers, hospitals and clinics in more than 100 countries. For more information, visit www.penumbrainc.com and connect on Twitter and LinkedIn.
Investor Relations
Penumbra, Inc.
510-995-2461
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$258.90 |
| Daily Change: | 0.52 0.20 |
| Daily Volume: | 336,566 |
| Market Cap: | US$9.940B |
June 05, 2025 May 20, 2025 April 23, 2025 | |
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORE
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
